URGN (UroGen Pharma Ltd. Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by URGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Mark Schoenberg | Chief Medical Officer | MIXED | — | — |
| 2026-09-09 | Jason Drew Smith | General Counsel | MIXED | — | — |
| 2026-08-28 | James A. Robinson Jr. | Director | M | — | — |
| 2026-08-24 | Mark Schoenberg | Chief Medical Officer | Sell | — | — |
| 2026-07-10 | Mark Schoenberg | Chief Medical Officer | Sell | — | — |
| 2026-06-24 | LEANA WEN | Director | A | — | — |
| 2026-06-24 | Mark Schoenberg | Chief Medical Officer | Sell | — | — |
| 2026-06-24 | CYNTHIA M BUTITTA | Director | A | — | — |
| 2026-06-24 | Arie Belldegrun | Director | A | — | — |
| 2026-06-24 | James A. Robinson Jr. | Director | A | — | — |
| 2026-06-24 | Stuart Holden | Director | A | — | — |
| 2026-06-24 | Daniel George Wildman | Director | A | — | — |
| 2026-06-09 | Mark Schoenberg | Chief Medical Officer | MIXED | — | — |
| 2026-05-27 | James A. Robinson Jr. | Director | M | — | — |
| 2026-05-11 | Mark Schoenberg | Chief Medical Officer | Sell | — | — |
| 2026-02-27 | James A. Robinson Jr. | Director | M | — | — |
| 2026-02-19 | Elizabeth A. Barrett | Chief Executive Officer | A | — | — |
| 2026-02-11 | Jason Drew Smith | General Counsel | MIXED | — | — |
| 2026-02-04 | Mark Schoenberg | Chief Medical Officer | Sell | — | — |
| 2026-02-03 | Chris Degnan | Chief Financial Officer | A | — | — |
| 2026-02-03 | Mark Schoenberg | Chief Medical Officer | M | — | — |
| 2025-12-01 | CYNTHIA M BUTITTA | Director | M | — | — |
| 2025-12-01 | Daniel George Wildman | Director | M | — | — |
| 2025-12-01 | James A. Robinson Jr. | Director | M | — | — |
| 2025-12-01 | LEANA WEN | Director | M | — | — |
| 2025-12-01 | Stuart Holden | Director | M | — | — |
| 2025-11-20 | Mark Schoenberg | Chief Medical Officer | Sell | — | — |
| 2025-10-09 | Chris Degnan | Chief Financial Officer | MIXED | — | — |
| 2025-09-09 | Jason Drew Smith | General Counsel | MIXED | — | — |
| 2025-09-09 | Mark Schoenberg | Chief Medical Officer | MIXED | — | — |
| 2025-08-27 | LEANA WEN | Director | A | — | — |
| 2025-08-27 | Daniel George Wildman | Director | A | — | — |
| 2025-08-27 | Stuart Holden | Director | A | — | — |
| 2025-08-27 | CYNTHIA M BUTITTA | Director | A | — | — |
| 2025-08-27 | James A. Robinson Jr. | Director | A | — | — |
| 2025-08-27 | Arie Belldegrun | Director | A | — | — |
| 2025-08-13 | Mark Schoenberg | Chief Medical Officer | Sell | — | — |
| 2025-07-30 | Elizabeth A. Barrett | Chief Executive Officer | A | — | — |
| 2025-07-30 | Mark Schoenberg | Chief Medical Officer | MIXED | — | — |
| 2025-07-30 | Jason Drew Smith | General Counsel | MIXED | — | — |
| 2025-06-11 | Mark Schoenberg | Chief Medical Officer | MIXED | — | — |
| 2025-02-04 | Elizabeth A. Barrett | Chief Executive Officer | A | — | — |
| 2025-02-04 | Jason Drew Smith | General Counsel | MIXED | — | — |
| 2025-02-04 | Mark Schoenberg | Chief Medical Officer | MIXED | — | — |
| 2024-10-09 | Chris Degnan | Chief Financial Officer | A | — | — |
| 2024-09-12 | Dong Kim | Chief Financial Officer | M | — | — |
| 2024-09-12 | Jason Drew Smith | General Counsel | MIXED | — | — |
| 2024-09-12 | Mark Schoenberg | Chief Medical Officer | MIXED | — | — |
| 2024-08-08 | LEANA WEN | Director | A | — | — |
| 2024-08-08 | Arie Belldegrun | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,437,169 | — |
| — | 10%+ Owner | 1,242,031 | — |
| — | Director | 408,693 | — |
| — | Chief Executive Officer | 326,691 | — |
| — | Director | 84,339 | — |
| — | Chief Medical Officer | 67,849 | — |
| — | General Counsel | 53,141 | — |
| — | Chief Financial Officer | 37,753 | — |
| — | Chief Financial Officer | 11,829 | — |
| — | Chief Operating Officer | 10,084 | — |
| — | Director | 8,000 | — |
| — | Chief Financial Officer | 5,579 | — |
| — | Chief Financial Officer | 2,280 | — |
| — | Director | 2,000 | — |
| — | Director | 2,000 | — |
| — | Director | 2,000 | — |
| — | Director | 2,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the URGN quote page; the site-wide leaderboard is on the insider transactions hub.